Francisco López-Muñoz1, Domenico De Berardis2, Michele Fornaro3, Federica Vellante4, Massimo di Giannantonio4, Francisco J Povedano-Montero5, Maria Póveda Fernández-Martín5, Gabriel Rubio6, Cecilio Álamo7. 1. Faculty of Health Sciences, Camilo José Cela University, Madrid, Spain - Neuropsychopharmacology Unit, Hospital 12 de Octubre Research Institute (i+12), Madrid, Spain - Portucalense Institute of Neuropsychology and Cognitive and Behavioural Neurosciences (INPP), Portucalense University, Porto, Portugal. 2. NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini", ASL 4, Teramo, Italy - Department of Neurosciences and Imaging and Clinical Sciences, University "G. D'Annunzio", Chieti, Italy. 3. Department of Psychiatry, Federico II University of Naples, Naples, Italy - New York State Psychiatric Institute (NYSPI), Columbia University, NYC, NY, USA. 4. Department of Neurosciences and Imaging and Clinical Sciences, University "G. D'Annunzio", Chieti, Italy. 5. Faculty of Health Sciences, Camilo José Cela University, Madrid, Spain. 6. Neuropsychopharmacology Unit, Hospital 12 de Octubre Research Institute (i+12), Madrid, Spain - Department of Psychiatry, "Doce de Octubre" University Hospital, Complutense University, Madrid, Spain. 7. Department of Biomedical Sciences (Pharmacology Area), Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Madrid, Spain.
Abstract
Objective: A bibliometric study of peer-reviewed scientific publications on atypical antipsychotic drugs (AADs) from Italy is herein presented. Methods: We selected the documents from Scopus database. We applied several bibliometric indicators of production and dispersion, including Price’s Law about the increase of scientific literature, and Bradford’s Law. We also calculated the participation index across different countries. The bibliometric data have also been correlated with some social and health data sourcing in Italy, such as total per capita expenditure on health and gross domestic expenditure. Results: A total of 2949 original documents were published within the period 1972-2015. Our results state fulfilment of Price’s Law, with scientific production showing exponential growth (r=0.901, as against an r=0.838 after linear adjustment). The drugs most widely studied were clozapine (257 documents), risperidone (179), and olanzapine (172). Stratification into Bradford zones yielded a nucleus represented by the Journal of Clinical Psychopharmacology and Rivista di Psichiatria (58 articles, each one). A total of 1091 different journals were evaluated. Conclusions: The publications on AADs in Italy have undergone exponential growth over the studied period, which is in line with the progressively burgeoning on novel AAD releases. No evidence of saturation point was observed.
Objective: A bibliometric study of peer-reviewed scientific publications on atypical antipsychotic drugs (AADs) from Italy is herein presented. Methods: We selected the documents from Scopus database. We applied several bibliometric indicators of production and dispersion, including Price’s Law about the increase of scientific literature, and Bradford’s Law. We also calculated the participation index across different countries. The bibliometric data have also been correlated with some social and health data sourcing in Italy, such as total per capita expenditure on health and gross domestic expenditure. Results: A total of 2949 original documents were published within the period 1972-2015. Our results state fulfilment of Price’s Law, with scientific production showing exponential growth (r=0.901, as against an r=0.838 after linear adjustment). The drugs most widely studied were clozapine (257 documents), risperidone (179), and olanzapine (172). Stratification into Bradford zones yielded a nucleus represented by the Journal of Clinical Psychopharmacology and Rivista di Psichiatria (58 articles, each one). A total of 1091 different journals were evaluated. Conclusions: The publications on AADs in Italy have undergone exponential growth over the studied period, which is in line with the progressively burgeoning on novel AAD releases. No evidence of saturation point was observed.
Authors: Francisco López-Muñoz; Derek K Tracy; F Javier Povedano-Montero; Josefien Breedvelt; Javier García-Pacios; Mª Poveda Fernández-Martín; Gabriel Rubio; Cecilio Álamo Journal: Ther Adv Psychopharmacol Date: 2019-02-14